Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA).
Mukherjee S, Ayanambakkam A, Ibrahimi S, Schmidt S, Charkrabarty JH, Khawandanah M. Mukherjee S, et al. Among authors: ibrahimi s. Hematol Oncol Stem Cell Ther. 2018 Sep;11(3):187-188. doi: 10.1016/j.hemonc.2017.12.004. Epub 2018 Feb 1. Hematol Oncol Stem Cell Ther. 2018. PMID: 29406240 Free article. Review.
Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center.
Borogovac A, Keruakous A, Bycko M, Holter Chakrabarty J, Ibrahimi S, Khawandanah M, Selby GB, Yuen C, Schmidt S, Autry MT, Al-Juhaishi T, Wieduwilt MJ, Asch AS. Borogovac A, et al. Among authors: ibrahimi s. Bone Marrow Transplant. 2022 Jun;57(6):1025-1027. doi: 10.1038/s41409-022-01664-z. Epub 2022 Apr 11. Bone Marrow Transplant. 2022. PMID: 35411106 Free PMC article. No abstract available.
Extranodal Marginal Zone Lymphoma of the Central Nervous System.
Ayanambakkam A, Ibrahimi S, Bilal K, Cherry MA. Ayanambakkam A, et al. Among authors: ibrahimi s. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):34-37.e8. doi: 10.1016/j.clml.2017.09.012. Epub 2017 Sep 23. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29103980 Review.
Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.
Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O'Connor DJ, Méndez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahimi S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, Monjazeb AM. Wang Z, et al. Among authors: ibrahimi s. Nat Med. 2019 Jan;25(1):141-151. doi: 10.1038/s41591-018-0221-5. Epub 2018 Nov 12. Nat Med. 2019. PMID: 30420753 Free PMC article.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS; TRANSFORM Investigators. Kamdar M, et al. Among authors: ibrahimi s. Lancet. 2022 Jun 18;399(10343):2294-2308. doi: 10.1016/S0140-6736(22)00662-6. Lancet. 2022. PMID: 35717989 Clinical Trial.
102 results